MDGL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.85%, SMA50 -13.21%, SMA200 4.95%). The stock’s 14-day RSI is 38.48 (weak momentum), while the ATR of 22.33 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -27.5% below its high and over 68.25% above its low. Average 10-day trading volume of 191.20 thousand shares is below the 3-month average of 345.62 thousand, indicating normal recent market interest.

Madrigal Pharmaceuticals, Inc. has 23.10 million shares outstanding. The public float is 13.72 million shares, elevated short interest at 10.00% of float. This equals 1.97 million shares. The short ratio is 5.41 days. Institutional investors hold 113.77% of the float. Insiders own 5.89%. Taub Rebecca holds 452.21 thousand shares, CRAVES FRED B has 350.08 thousand shares and Sibold William John has 209.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.91 thousand shares across 5 transactions.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) closed at $533.12 USD, losing -$13.54 (-2.48%) from the previous close of $546.66. The stock is currently mid-range between its 52-week high and low $393.61 and $615.00. With a market capitalization of about $12.32 billion, Madrigal Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~-0.99). Key stats such as the average daily volume over the past year has been around 349.54 thousand shares, volume is running light vs its 52-week average. Headquartered in West Conshohocken, PA, Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William J. Sibold, the company employs approximately 915 people and listed since February 06, 2007. Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders.

Madrigal Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.14 thousand. This means the shares are trading below this model’s fair value.

Madrigal Pharmaceuticals, Inc. generated EPS of -$12.86 over the past year. Five-year average earnings growth is 0.37%. The latest quarter delivered EPS of -$1.99. The next quarter is forecast at -$3.68. Next year's EPS is expected at $14.03. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 12 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $964.00 to $445.00. The high target offers 80.82% upside. The low target suggests -16.53% downside. The mean target is $639.19. This offers 19.9% upside. Madrigal Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended July 30, 2026, missed forecasts by -25.75%. The prior quarter beat by -9.97%. Over the last six quarters, Apple has recorded several small beats. These include -8.29% in May 01, 2025.

Madrigal Pharmaceuticals, Inc. trades at a P/E ratio of -40.49, slightly below the S&P 500 average, with a price-to-sales ratio of 9.39 and a price-to-book ratio of 29.04 reflecting a rich premium to book value. The P/FCF stands at -58.45, also below market averages. Compared to sector medians, Madrigal Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares are down -13.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Madrigal Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -40.49. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $409.08, suggesting -23.27% downside. Our AI forecast model points to short-term strength (4.96% over two weeks), a medium-term rise (10.3% over three months), and a longer-term gain (25.59% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Madrigal Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.96%, with price expected at $559.54 by September 23, 2026, within a range of $541.66 to $576.49 3-Month Outlook: Projected rise of 10.3%, reaching $588.02 by December 08, 2026, with a range of $582.27 to $594.68. 1-Year Outlook: Projected gain of 25.59%, with price at $669.56 by September 09, 2027, within a range of $655.38 to $693.03.